PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: Perform Group Tops FTSE 250, Up Over 25%

Mon, 01st Sep 2014 10:51

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Monday.
-------
FTSE 100 LOSERS
-------
Tesco, down 1.6%. The supermarket continues to fall after it cut profit expectations last week. Major shareholder, David Herro, told the Sunday Telegraph he has cut his investment from around 3% to 1% due to the absence of a clear strategy.

GlaxoSmithKline, down 0.9%. The company faces a potential shareholder revolt from investors calling for Chairman Chris Gent to leave more quickly, the Sunday Times reported, citing a senior City source. Several big institutions are calling for the chairman or chief executive to leave this year due to Glaxo's poor share price performance and growing corruption claims, the report said. Gent has said he will stand down next year, and is likely to be succeeded by Royal Bank of Scotland Group Chairman Philip Hampton.
-------
FTSE 250 WINNERS
-------
Perform Group, up 26%. The digital media company urged its shareholders to take no action after the US's Access Industries Group made a final cash offer to acquire all of the shares in the company it does not already own for 260 pence per share, valuing the company at GBP701.6 million. Perform reiterated its confidence in its standalone strategy and growth prospects, and said it remains focussed on "delivering significant value for all shareholders." Access said the bid was final and would not be increased.
-------
FTSE 250 LOSERS
-------
Ocado Group, 1.6%. The company has had its rating cut by Exane BNP to Underperform, from Neutral, and its price target cut to 265 pence, from 300p. The stock is trading at 324.1p

Spirax-Sarco Engineering, down 1.6%. The company had its rating cut by Numis to Hold, from Add, and a price target cut to 3,000 pence, from 3,050p.
-------
AIM ALL-SHARE WINNERS
-------
Seeing Machines, up 26%. The company said that it had signed a 15-year strategic alliance with advanced driver safety systems company Takata Corp's American subsidiary TK Holdings Inc. The two companies have been working together on driver monitoring technology for two years, Seeing Machines said, and Takata recently won a contract to implement a mass-manufactured driver-monitoring system. Seeing Machines will see revenues from a combination of minimum licence fees and royalties, it said. The two will also look at opportunities beyond passenger cars into all forms of road vehicles, it said.

Forbidden Technologies, up 18%. The company said that the first alpha testing versions of its social video platform 'eva' have been released, and customers can now apply to join the test. 'Eva' is a video editing and sharing platform based on Forbidden's FORScene cloud video platform. The alpha test is designed to test specific features and infrastructure which are beyond what would have been possible with earlier prototypes, it said.

Crimson Tide, up 18%. The company said that it has signed a "transformational" contract with a global food company which is expected to generate contracted margin revenue of GBP250,000 during the term. Under the terms of the agreement, which will last in excess of three years, Crimson Tide's mpro5 system will provide the client with Proof of Delivery and Estimated Time of Arrival information for its own and third party deliveries. mpro5 will communicate with the client's SAP system to collect and receive delivery data from mobile devices used by drivers and delivery workers. Upon the achievement of an extended worldwide rollout - which will commence in Australia "imminently" - the size of the contracted margin revenue could rise significantly above GBP250,000, conditional on the number of users, said the mobile solutions provider.
-------

By Neil Thakrar; neilthakrar@alliancenews.com

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.